Urokinase - Biologic Drug Details

Summary for urokinase

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for urokinase

Recent Clinical Trials for urokinase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Capital Medical University	NA
Odense University Hospital	PHASE2
Beijing Tiantan Hospital	NA

See all urokinase clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for urokinase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for urokinase Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for urokinase Derived from Patent Text Search

No patents found based on company disclosures

Urokinase Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Urokinase?

Urokinase, a serine protease originally derived from human embryonic kidney cells, is a thrombolytic agent primarily used to dissolve blood clots. It plays a vital role in treating conditions such as pulmonary embolism, deep vein thrombosis, and acute myocardial infarction.

Market drivers include rising incidence of thromboembolic diseases, aging populations, and increasing awareness of minimally invasive procedures that favor thrombolytics. The global thrombolytic drug market was valued at approximately $2 billion in 2022, with urokinase representing around 15% of this market. The therapy's preference in regions with strict regulatory standards, like Japan and China, sustains demand.

Regulatory landscapes impact availability: in the United States, urokinase has been withdrawn from the market for commercial use, replaced by tissue plasminogen activator (tPA). Conversely, in Asia, it remains accessible, with local manufacturing supporting steady supply.

The presence of alternative thrombolytics, such as tPA and newer agents like tenecteplase, impacts urokinase's market share. The latter drugs often demonstrate improved safety profiles and dosing convenience, influencing prescriber preferences.

What Is the Financial Trajectory for Urokinase?

The financial outlook for urokinase differs across regions due to regulatory, market, and manufacturing factors:

Revenue Trends

• Global revenue declined from approximately $300 million in 2019 to about $250 million in 2022, driven by market withdrawal in Western countries and increased competition from tPA variants.
• Asia maintains consistent demand, resulting in regional sales of roughly $125 million in 2022, supported by local manufacturing and established use in hospitals.

Cost and Pricing

• Urokinase remains an inexpensive option, with wholesale prices around $10 to $20 per dose in Asia, versus over $100 per dose for tPA in Western markets.
• Manufacturing costs are relatively stable owing to established extraction and recombinant methods. Patent protections have expired, challenging early market dominance and leading to increased generic availability and price erosion.

Supply and Manufacturing

• Several manufacturing sources, primarily in China and India, produce recombinant and plasma-derived versions. The supply is stable but vulnerable to geopolitical influences and regulatory scrutiny.
• In the U.S., the drug was withdrawn by the manufacturer, Kelun Pharmaceutical, around 2010, after their patent expired and sales declined.

Investment and R&D Trends

• No current major R&D pipeline exists for urokinase. Most research focuses on new thrombolytic agents with improved safety, efficacy, and ease of administration.
• Biotech and pharmaceutical companies are shifting investment toward tissue plasminogen activator derivatives and alternative clot-dissolving therapies.

How Do Regulatory Policies Affect the Market?

The regulatory landscape influences urokinase’s availability and economics:

• United States: Urokinase received regulatory approval in the 1980s but was withdrawn from the U.S. market, primarily due to the emergence of tPA and its patent protections. Current regulations classify urokinase as a biosimilar or formerly approved biologic, limiting reentry opportunities.
• Europe: Urokinase remains available but is seldom used given the preference for tPA and recent approvals of newer agents.
• Asia: Regulatory pathways are less restrictive, supporting local manufacturing, use, and export. Little governmental intervention affects supply.

What Are the Competitive and Market-Specific Factors?

• Competitors: Tissue plasminogen activators (tPA, tenecteplase) dominate markets with better safety profiles and dosing ease.
• Market niches: Urokinase remains relevant in regions with limited access to newer agents or where cost is a primary consideration.
• Manufacturing: Chinese and Indian producers account for a significant share, offering lower-cost recombinant urokinase derivatives.

What Are the Key Challenges and Opportunities?

• Challenges:
  • Limited R&D investment, with focus shifting to newer pharmaceuticals.
  • Regulatory barriers in Western countries.
  • Competition from advanced thrombolytics with superior safety profiles.
• Opportunities:
  • Expanding use in countries with constrained healthcare budgets.
  • Developing biosimilar formulations to reduce costs further.
  • Potential for combination therapies or new indications within thrombotic diseases.

Summary of Financial Outlook

Parameter	2022 Data	Future Outlook
Global market size	~$250 million	Likely to decline in Western markets, stabilize in Asia
Regional sales	Asia: ~$125 million	Growth driven by local manufacturing
Pricing	$10–$20 per dose (Asia); >$100 (Western)	Price erosion expected as generics proliferate
R&D activity	Minimal	Limited, with focus on new agents

Key Takeaways

Urokinase holds a limited but regionally significant role. While declining in Western markets due to regulatory and competitive pressures, it remains a low-cost alternative in Asia. Market prospects depend heavily on regional healthcare policies, manufacturing capabilities, and the pace of innovation in thrombolytic therapy.

FAQs

1. Why has urokinase been withdrawn from the U.S. market?
The drug was withdrawn mainly due to the advent of tissue plasminogen activators (tPAs), patent expiration, and declining demand, compounded by safety and efficacy concerns favoring newer agents.

2. What are the main competitors to urokinase?
Tissue plasminogen activators such as alteplase (tPA), tenecteplase, and reteplase dominate the thrombolytic market worldwide.

3. Is urokinase still used in clinical practice?
Yes, particularly in Asia and developing countries where it remains affordable and accessible.

4. What are the future prospects for urokinase?
Limited; opportunities exist mainly in regions with less access to newer thrombolytics or in cost-sensitive markets.

5. Are there ongoing R&D efforts for urokinase?
No significant pipeline exists; focus is shifting toward developing new thrombolytics with improved safety or alternative treatments for thrombotic conditions.

---

References

1. MarketsandMarkets, "Thrombolytic Drugs Market," 2022.
2. U.S. Food and Drug Administration, "Drug Approvals and Market Status," 2010.
3. European Medicines Agency, "Market Authorization Status," 2022.
4. Research papers on thrombolytic agents and regional usage patterns, PubMed, 2021.
5. Kelun Pharmaceutical Annual Reports, 2019–2022.